Search
BIO-Europe: Dicot Pharma's CEO talks about moving the company's ED candidate into a phase 2a in multiple nordic countries - plus a stock market uplisting
Elin Trampe describes the unmet need the company believes exists for ED today, the history of their drug and how it was invented in...
Nov 4, 2024
BIO-Europe: The CEO of Sweden's Affibody on trying to be better than antibodies, moving into the radiopharmaceutical space, and IPO rumors
David Bejker describes how affibody's are meant to compete with monoclonal antibodies, which the company's lead program in IL-17. Plus,...
Nov 4, 2024
BIO-Europe: Spain's Integra Therapeutics announced today that it has licensed novel Cas12l nucleases from Lithuania-based Caszyme as it continues to develop its gene writing platform
Integra CEO Avencia Sánchez-MejÃas and Caszyme CEO Monika PaulÄ— discuss the deal and explain why Cas12l's small size gives it...
Nov 4, 2024
BIO-Europe: Sweden's Alligator Bioscience is ready for P3 for its CD40 program in pancreatic cancer - the company is looking for a partner as its first choice to move it forward
CEO Søren Bregenholt describes this program, and why Alligator chose pancreatic cancer. Plus, he discusses CD40 x CEA(CAM5) and 4-1BB x...
Nov 4, 2024
BIO-Europe: Germany based HepaRegeniX is targeting MKK4 to spur regeneration in diseased livers. This year the company has published clinical data and raised a series C
CEO Elias Papatheodorou describes the unmet need in liver disease and the rationale for MKK4, a target HepaRegeniX is focused on and is...
Nov 4, 2024
Dallas based Etira is aiming to cause apoptosis in cancer cells by targeting LIPA and thus inducing stress in the endoplasmic reticulum
CEO Russell Hayward describes the scientific rationale of this approach, as well as how the company may be weeks away from dosing its...
Oct 30, 2024
A UT Southwestern neurology expert and the CEO of GenrAb discuss neuro-immunology and finding antibodies that can help with neuronal damage
UTSW's Dr. Ben Greenberg discusses how neuro-immunology is making inroads for conditions like MS, ALS, and alzheimer's. GenrAb CEO Larry...
Oct 30, 2024
Southlake, TX based OncoNano Medicine is harnessing nanotechnology to identify and target cancer - a lead program hits the STING pathway
CFO Matthew Head describes the company's ON-BOARD platform and how they are not only developing therapeutics, but also an imaging product...
Oct 29, 2024
An investigator from MGH and the CSO of Inozyme discuss p1 data at Kidney Week showing that INZ-701 raised the levels of inorganic pyrophosphate, making it a possible treatment for calciphylaxis
Sagar Nigwekar and Yves Sabbagh describe the problem of calciphylaxis, and why they believe that raising the levels of PPi could have an...
Oct 27, 2024
Vera's CEO discusses the 96-week follow up results for Atacicept in IgAN that were presented this weekend at Kidney Week in San Diego
Marshall Fordyce discusses the results for this fusion protein that binds to both BAFF and APRIL. The company says it saw eGFR...
Oct 27, 2024
Purespring Therapeutics raised a $105M series B earlier this month to advance AAV gene therapies for kidney diseases, including both monogenic and non-monogenic diseases
CEO Julian Hanak describes how Purespring focuses on targeting podocytes, a cell type that plays a role in various kidney diseases. Key...
Oct 24, 2024
SecondWave Systems is using low intensity ultrasound to treat inflammatory conditions like RA
Co-Founder & CEO Anuj Bhardwaj describes the device SecondWave has developed and how it is designed to hit the spleen with ultrasound,...
Oct 21, 2024
San Diego based Libra Therapeutics is aiming to boost protein clearance in neurodegenerative diseases by targeting TRPML1
Chief Business Officer Isaac Veinbergs describes this approach and how Libra is focuses on ALS as a first indication.
Oct 21, 2024
Cambridge, MA based Lytica Therapeutics is trying to make antibody-drug conjugates more efficient by designing the antibody portion in a way that makes cells internalize them better
Co-Founder and CEO Rida Mourtada describes how Lytica is adding a peptidic sequence to antibodies to improve their internalization into...
Oct 21, 2024
Since winning a pitch competition a year ago, Synthis Therapeutics has been working out of JLABS' Manhattan location on a TGF-β antibody drug conjugate
Founder & CEO Dori Thomas-Karyat describes why she believes a local delivery approach to the tumor is the solution to the shortcomings...
Oct 21, 2024
Entrepreneur Pierluigi Paracchi on San Raffaele, biotech in Italy, and his company Genenta Science
A leading voice in Italy's biotech community, he describes the world-class work that takes place at his home base of Ospedale San...
Oct 18, 2024
Milan based Enthera Pharmaceuticals is working in the autoimmune space with an asset that targets a unique pathway and that is the result of local research
CEO Lisa Olson describes the IGFBP3/TMEM219 axis and the antibody Enthera has designed to target it, all of which are the result of...
Oct 17, 2024
Lundbeck CEO Charl van Zyl describes the rationale for today's $2.6 billion acquisition of Longboard Pharma
He explains the market opportunity he sees for Bexicaserin and the data that made him comfortable to pull the trigger on the deal today...
Oct 14, 2024
Ghent based Confo Therapeutics is leveraging GPCR expertise as a discovery engine - multiple partners have already signed on to the science
CEO Cedric Ververken walks us through what separates Confo from other GPCR developers, and discusses pipeline programs in pain, obesity,...
Oct 14, 2024
Copenhagen based FluoGuide is working to light up tumors for surgeons by guiding fluorescent molecules to uPAR - a target that has been studied widely in Scandinavia
CEO Morten Albrechtsen describes the rational for this target for this purpose and how they FluoGuide has designed its fluorescent agent....
Oct 11, 2024
.png){kind=logo}
